SAN DIEGO, January 11, 2022 – Meet Antonius Schuh, Ph.D. (CEO), Andreas Klostermann, Ph.D. (CSO) and Steve Zaniboni (CFO) for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work.